L'intérêt à découvert pour Amedisys donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Amedisys. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Amedisys (NASDAQ:AMED) Stock, Rapport sur les intérêts à découvert

Amedisys

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Amedisys Inc

AMEDEO AIR FOUR PLUS LTD by AMEDEO AIR FOUR PLUS LTD

On Tuesday, the U.S. Justice Department said it will block UnitedHealth Group Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) multi-billion&nbsp;acquisition of&nbsp;Amedisys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns about competition in the home <a target="_blank" href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on" rel="noreferrer noopener">health services market</a>.
UnitedHealth&#8217;s Optum unit&nbsp;launched a website&nbsp;that aims to highlight the benefits of the combination. The website <a target="_blank" href="https://www.improvinghomecare.com/" rel="noreferrer noopener">notes</a> that the home healthcare industry remains highly fragmented despite the growing market.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
On average, 26 agencies compete in metropolitan areas with about 500,000 residents, highlighting the range of available care options.
In 2020, approximately 3 million Americans received home health care, a figure expected to grow as the population ages.
By 2030, 18% of the U.S. population will be 65 or older, a significant increase from 13% in 2021.
This demographic shift underscores the necessity for expanded home health services that allow older adults to remain in their homes.
The merger between Optum and Amedisys represents a strategic move to address these needs.
While this combined entity would represent only a portion of the overall home health and hospice care market, the competitive landscape is expected to remain robust.
To promote competition and prevent market dominance, Optum and Amedisys have agreed to divest numerous home health and hospice centers to VitalCaring upon the transaction&#8217;s completion.
VitalCaring currently operates at around 58 locations across six states.
Price Action: UNH stock is down 2.76% at $589.17 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41979149/general-motors-faces-recall-crisis-with-faulty-transmissions-details" target="_blank" rel="noreferrer noopener">General Motors Faces Recall Crisis With Faulty Transmissions: Details</a></li>
</ul>
Image via Shutterstock

Large Cap

News

Health Care

Legal

General

AMED

UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape

UnitedHealth Says 'Will Vigorously Defend Against The DOJ's Overreaching'

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.
What To Know: The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.
Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.
&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;Jonathan Kanter&nbsp;said.
The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. 
The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.
United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.
UNH Price Action: UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of UnitedHealth.

Movers

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

<a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines">https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines</a>
&nbsp;
The Justice Department on Tuesday sued to block <a href="https://www.wsj.com/market-data/quotes/UNH">UnitedHealth Group</a>'s $3.3 billion acquisition of <a href="https://www.wsj.com/market-data/quotes/AMED">Amedisys</a> alleging the deal would give the <a href="https://www.wsj.com/health/healthcare/unitedhealth-shares-dive-after-health-giant-says-2025-results-likely-to-fall-short-8a7ff76a?mod=article_inline">health-industry giant</a> too much power over the market for home health and hospice services.
The government's move represents an effort to stem the roll-up of different healthcare services under a single owner. UnitedHealth last year acquired one of Amedisys's major competitors, LHC Group.&nbsp;

"Justice Department Sues To Block UnitedHealth's $3.3B Bid For Amedisys; Antitrust Enforcers Argue The Healthcare Giant's Latest Deal Would Illegally Harm Competition" - WSJ

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $1.00 per share which missed the analyst consensus estimate of $1.17 by 14.53 percent. This is a 2.04 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $587.70 million which beat the analyst consensus estimate of $586.49 million by 0.21 percent. This is a 5.66 percent increase over sales of $556.24 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Amedisys Q3 EPS $1.00 Misses $1.17 Estimate, Sales $587.70M Beat $586.49M Estimate

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) and Chemed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/che#NYSE">CHE</a>). But which of these two stocks presents investors with the better value opportunity right now? Let&#39;s take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Amedisys and Chemed are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that AMED has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 20.73, while CHE has a forward P/E of 25.41. We also note that AMED has a PEG ratio of 1.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. CHE currently has a PEG ratio of 2.26.
Another notable valuation metric for AMED is its P/B ratio of 2.68. Investors use the P/B ratio to look at a stock&#39;s market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CHE has a P/B of 7.47.
These metrics, and several others, help AMED earn a Value grade of B, while CHE has been given a Value grade of C.
AMED stands above CHE thanks to its solid earnings outlook, and based on these valuation figures, we also feel that AMED is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2343525/amed-or-che-which-is-the-better-value-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2343525">To read this article on Zacks.com click here.</a>

Markets

Trading Ideas

AMED Or CHE: Which Is The Better Value Stock Right Now?

Contessa Health, A Subsidiary Of Amedisys Announced They Have Been Selected By The Centers For Medicare & Medicaid Services To Participate In A New Medicare Alternative Payment Model Designed To Support People Living With Dementia And Their Caregivers

Deutsche Bank analyst Justin Bowers downgrades Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Buy to Hold and maintains the price target from $101 to $101.

Downgrades

Price Target

Analyst Ratings

Deutsche Bank Downgrades Amedisys to Hold, Maintains Price Target to $101

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) or U.S. Physical Therapy (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usph#NYSE">USPH</a>). But which of these two stocks is more attractive to value investors? We&#39;ll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Amedisys has a Zacks Rank of #2 (Buy), while U.S. Physical Therapy has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that AMED likely has seen a stronger improvement to its earnings outlook than USPH has recently. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 21.14, while USPH has a forward P/E of 34.11. We also note that AMED has a PEG ratio of 2.37. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company&#39;s expected earnings growth rate. USPH currently has a PEG ratio of 3.77.
Another notable valuation metric for AMED is its P/B ratio of 2.80. The P/B ratio is used to compare a stock&#39;s market value with its book value, which is defined as total assets minus total liabilities. For comparison, USPH has a P/B of 3.04.
These are just a few of the metrics contributing to AMED&#39;s Value grade of B and USPH&#39;s Value grade of C.
AMED is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that AMED is likely the superior value option right now.
<a href="https://www.zacks.com/stock/news/2310183/amed-vs-usph-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2310183">To read this article on Zacks.com click here.</a>

Small Cap

USPH

AMED vs. USPH: Which Stock Is the Better Value Option?

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and maintains $101 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.18 by 11.86 percent. This is a 3.65 percent decrease over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $591.19 million which beat the analyst consensus estimate of $578.82 million by 2.14 percent. This is a 6.91 percent increase over sales of $552.97 million the same period last year.

Amedisys Q2 EPS $1.32 Beats $1.18 Estimate, Sales $591.19M Beat $578.82M Estimate

William Blair analyst Matt Larew downgrades Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Outperform to Market Perform.

William Blair Downgrades Amedisys to Market Perform

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.98 percent. The company reported quarterly sales of $571.400 million which beat the analyst consensus estimate of $565.380 million by 1.06 percent. This is a 2.70 percent increase over sales of $556.389 million the same period last year.

Amedisys Q1 2024 Adj EPS $1.03 Beats $1.02 Estimate, Sales $571.400M Beat $565.380M Estimate

Raymond James analyst John Ransom maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Market Perform to Market Perform.

Raymond James Maintains Market Perform on Amedisysto Market Perform

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Outperform and raises the price target from $97 to $100.

RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $100

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by 8.74 percent. The company reported quarterly sales of $570.800 million which beat the analyst consensus estimate of $567.713 million by 0.54 percent. This is a 1.55 percent increase over sales of $562.064 million the same period last year.

Amedisys Q4 2023 Adj EPS $0.940 Misses $1.030 Estimate, Sales $570.800M Beat $567.713M Estimate

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8.74 percent. The company reported quarterly sales of $570.80 million which beat the analyst consensus estimate of $567.71 million by 0.54 percent. This is a 1.55 percent increase over sales of $562.06 million the same period last year.

Amedisys Q4 2023 Adj EPS $0.94 Misses $1.03 Estimate, Sales $570.80M Beat $567.71M Estimate

Amedisys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes. &nbsp;
Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers rapid and precise results, ultimately enabling quicker initiation of appropriate treatment interventions. With improved accuracy, sensitivity and specificity, molecular testing significantly enhances the ability to identify infectious pathogens, supporting timely and targeted care strategies.
"We are excited to integrate molecular testing capabilities into our infection diagnosis protocols," states Cyndi Shook, Senior Vice President of Clinical Operations at Amedisys. "This advancement represents a significant step in our ongoing commitment to providing the highest quality of care to our patients. By leveraging the latest in diagnostic technology, we can further enhance the accuracy and speed of infection testing, allowing us to tailor treatment plans to the individual needs of each patient."
"Patients Choice Laboratories is excited to partner with Amedisys, one of the leaders in the home health industry, in an effort to improve outcomes for patients suffering from infectious diseases," said Brad Moss, President at Patients Choice Laboratories. "Our automated pre-analytical, analytical and post-analytical processes in molecular technologies provide the necessary clinical decision support so that treatments are targeted and successful."
"According to the CDC, more than one-third of deaths of people over the age of 65 are caused by infectious diseases, thus making turnaround time critical so that the most appropriate treatment(s) are deployed in the early stages of infection," added Thomas Payne, Chief Operations Officer at Patients Choice Laboratories. "Molecular testing provides the speed and accuracy needed to detect pathogens across our entire infectious disease platform."
"Our partnership with Patient Choice Laboratories aligns seamlessly with our dedication to delivering exceptional care and optimizing patient outcomes," added Barbara Andazola, Vice President of Clinical Practice, Strategy and Programs at Amedisys. "By incorporating molecular testing into our infection diagnosis protocols, we are empowering our care teams to provide more accurate and effective treatments, ultimately reducing the impact of infections and preventing related hospitalizations."
Amedisys has implemented comprehensive protocols and training to ensure seamless integration of molecular testing into its care centers. The rollout of this innovative approach to infection diagnosis underscores the organization's commitment to staying at the forefront of healthcare advancements and technology, ultimately providing its patients with the highest standard of care and support.
For more information about Amedisys Home Health and its advanced molecular testing capabilities, please visit <a href="http://www.amedisys.com/">www.amedisys.com</a>.

Biotech

Amedisys Offers Molecular Testing For Rapid And Accurate Infection Diagnosis In Collaboration With Patient Choice Laboratories

Richard Ashworth, President and CEO at Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), reported a large exercise of company stock options on December 28, according to a new SEC filing.
What Happened: Ashworth, President and CEO at Amedisys, made a strategic move by exercising stock options for 11,237 shares of AMED as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000896262/000089626223000081//Archives/edgar/data/896262/000089626223000081/0000896262-23-000081-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $171,027.
Amedisys shares are trading down 0.0% at $95.04 at the time of this writing on Friday morning. Since the current price is $95.04, this makes Ashworth's 11,237 shares worth $171,027.
<h3>Get to Know Amedisys Better</h3>
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
<h3>Amedisys's Financial Performance</h3>
Revenue Growth: Amedisys's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -0.31%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 43.98%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Amedisys's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.8.
</li>
</ul>
Debt Management: Amedisys's debt-to-equity ratio is below the industry average. With a ratio of 0.47, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 1188.0 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.39, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Amedisys's EV/EBITDA ratio of 25.02 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896262">Check Out The Full List Of Amedisys's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Richard Ashworth Exercises Options, Realizes $171K

In a report released today, Ryan Langston from TD Cowen maintained a Hold rating on Amedisys (AMED – Research Report), with a price target of $101....

TD Cowen Sticks to Its Hold Rating for Amedisys (AMED)

Amedisys sinks after report DOJ leaning toward challenging UnitedHealth deal

Amedisys drops on report DOJ preparing lawsuit to block UnitedHealth deal

Amedisys falls as DOJ sues to block $3.3B sale to UnitedHealth

12:02 EST Justice Department sues to block UnitedHealth (UNH) takeover of Amedisys (AMED) Published first on TheFly – the ultimate source for real-...

Justice Department sues to block UnitedHealth takeover of Amedisys

The Justice Department, together with the Attorneys General of Maryland, Illinois, New Jersey, and New York, confirmed filing a civil antitrust law...

DOJ, state AGs sue to block UnitedHealth's acquisition of Amedisys

In a lawsuit filed by the U.S. Department of Justice, Antitrust Division, in the U.S. District Court for the District of Maryland, the DOJ states: ...

Department of Justice files suit to block UnitedHealth, Amedisys merger

Following today's DOJ legal action aimed at blocking the proposed combination of UnitedHealth's (UNH) Optum and Amedisys (AMED), Optum has issued t...

UnitedHealth says 'will vigorously defend against the DOJ's overreaching'

Amedisys falls as DOJ sues to block $3.3B sale to UnitedHealth (update)

Unusual total active option classes on open include: Weyerhaeuser (WY), RealReal (REAL), Guggenheim S&P 500 Equal Weight (RSP), Amedisys (AMED), Tr...

Unusually active option classes on open November 13th

ACHR

JBLU

LUNR

REAL

RIVN

SPCE

TRIP

Press Releases

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

Amedisys Reports First Quarter 2024 Financial Results

AREX Capital Management Issues Letter to Enhabit Stockholders Regarding the Need for Dramatic Changes to Board Composition

Amedisys Reports Second Quarter 2024 Financial Results

Contracts

Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model

Amedisys has earned the 2023 SHPBest™ Patient Satisfaction Awards

Amedisys Reports Third Quarter 2024 Financial Results

ADUS

EHAB

TUES

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Amedisys

Intérêt court

Amedisys (NASDAQ:AMED) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL